贝伐单抗与卡铂结合治疗非小细胞肺癌恶性胸腔积液的疗效  

The Efficacy of Bevacizumab Combined with Carboplatin in the Treatment of Malignant Pleural Effusion of Non-small Cell Lung Cancer

作　　者：陈婧[1] 李冬雷[1] 张旭宇[1] 高玉华[1] 王艳丽[1] CHEN Jing;LI Donglei;ZHANG Xuyu(Second Central Hospital of Baoding,Baoding,072750)

机构地区：[1]河北省保定市第二中心医院

出　　处：《实用癌症杂志》2020年第2期208-211,共4页The Practical Journal of Cancer

基　　金：河北省2018年度医学科学研究重点课题计划项目(编号:20181062)

摘　　要：目的探究贝伐单抗联合卡铂治疗非小细胞肺癌恶性胸腔积液的有效性。方法将60例非小细胞肺癌恶性胸腔积液患者作为研究对象,根据入院先后实施分组,对照组30例,给予单纯卡铂治疗;观察组30例,在对照组基础上加用贝伐单抗治疗,对两组患者治疗前后的胸腔积液肿瘤标志物含量、血管新生分子、侵袭性生长分子含量以及临床治疗效果进行综合评价。结果观察组患者治疗后的胸腔积液中CEA、SCCAg等肿瘤标志物含量明显降低,与对照组比较差异显著(P<0.05),有统计学意义;观察组治疗后的VEGF、VEGFR及PTN血管新生分子含量减少,且减少幅度大于对照组(P<0.05),存在统计学意义;与对照组相比,观察组患者治疗后胸腔积液中各项侵袭性生长分子含量均显著改善(P<0.05),与对照组差异存在统计学意义;且观察组治疗后有27例患者显示有效,占90.0%,显著高于对照组的66.7%,两组差异较大(P<0.05),统计学有意义。结论贝伐单抗联合卡铂治疗非小细胞肺癌恶性胸腔积液,能够对血管新生及细胞侵袭起到抑制作用,促进癌细胞死亡,效果显著,值得推广应用。Objective To explore the efficacy of bevacizumab combined with carboplatin in the treatment of malignant pleural effusion of non-small cell lung cancer.Methods 60 patients with non-small cell lung cancer with malignant pleural effusion as the research object,the control group 30 cases was give simple carboplatin treatment;the observation group 30 cases on the basis of the control group received bevacizumab,the 2 groups of patients before and after treatment of pleural effusions tumor markers content,content of angiogenic molecules,invasive growth of molecular and clinical therapeutic effect of comprehensive evaluation were evaluated.Results The contents of CEA,SCCAg and other tumor markers in the pleural effusion after treatment significantly reduced,and the difference was significant(P<0.05),which was statistically significant.The contents of VEGF,VEGFR and PTN decreased in the observation group after treatment,and the decrease was greater than that of the control group(P<0.05),and there was statistical significance.Compared with the control group,the contents of invasive growth molecules in the pleural effusion were significantly improved after treatment(P<0.05),which was statistically significant with the control group.In addition,27 patients were shown to be effective in the observation group after treatment,accounting for 90.0%,significantly higher than 66.7%in the control group,and the difference between the 2 groups was significant(P<0.05),which was statistically significant.Conclusion Bevacizumab plus carboplatin in the treatment of non-small cell lung cancer with malignant pleural effusion,is capable of angiogenesis and cell invasion inhibition effect,promotes cancer cell death,the effect is remarkable,it is worthy of popularization and application.

关 键 词：贝伐单抗 卡铂 非小细胞肺癌 恶性胸腔积液 血管新生 侵袭 

分 类 号：R734.2[医药卫生—肿瘤]